Wells Fargo Starts First Tracks Biotherapeutics (TRAX) at Overweight Jun 8, 2026 05:00AM
Piper Sandler Starts First Tracks Biotherapeutics (TRAX) at Overweight May 4, 2026 02:16AM
H.C. Wainwright Starts First Tracks Biotherapeutics (TRAX) at Buy Apr 28, 2026 06:04AM
Wedbush Starts First Tracks Biotherapeutics (TRAX) at Outperform Apr 24, 2026 07:08AM
Leerink Partners Starts First Tracks Biotherapeutics (TRAX) at Outperform Apr 24, 2026 06:07AM


Apr 23, 2026 12:58AM JPMorgan Starts First Tracks Biotherapeutics (TRAX) at Overweight
Apr 22, 2026 02:51AM Barclays Starts First Tracks Biotherapeutics (TRAX) at Overweight
Apr 21, 2026 03:18AM UBS Starts First Tracks Biotherapeutics (TRAX) at Buy
Mar 31, 2026 06:42AM H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)
Mar 4, 2026 06:45AM AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright
Mar 4, 2026 05:48AM Guggenheim on AnaptysBio (ANAB) Spinoff: 'Additional potential upside may be derived from imsidolimab in generalized pustular psoriasis'